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Abstract  For  long-term  lipid  apheresis  therapy,  several 
different  technical  systems  have  been  developed  which 
enable  effective  reduction  of  LDL  cholesterol  and  other 
atherogenic lipoproteins, such as Lp(a), with sufficient se-
lectivity  and  good  clinical  tolerance.  Suitable  techniques 





The  technical  features  are  described.  Only  intensive 
training  and  experience  of  the medical  personnel  guaran-






progressed  considerably.  At  present,  6  different  systems 
are  available which  have  been  approved  by  the  technical 
surveillance  institute—called  TÜV—and  been  awarded  a 
so-called CE-sign. All  systems now have  fully  automated 
process management. A  continuous manual  steering  is  no 
longer necessary.
All  methods  fulfill  the  current  legal  requirements  for 












































































treatment with  this  technique,  improvement  in membrane 
technology has made the loss of HDL and serum proteins, 


















presence  of  unfractionated  heparin. After  plasma  separa-





absorbed  by  a  DEAE-cellulose-adsorber.  Finally,  the  low 
pH plasma is buffered by a single path bicarbonate hemo-
diafiltration.  For  anticoagulation  of  the  blood  circulation, 
fractionated  and  unfractionated  heparin  can  be  used.  The 
size of precipitation filter and adsorber has been increased, 
now enabling treatment of up to 4 L of plasma.
Despite  the  complex  procedure,  a  considerable  sim-
plification  and  shortening  of  treatment  has  been  achieved 







The  adsorption  principle  has  been  described  above.  The 
system  is  designed  for  single  use.  Adsorption  of  HDL 









Lipid filtration HELP DALI DSA LA
LDL cholesterol (%) 61–68 55–61 53–76 49–75 62–69
HDL cholesterol (%) 6–17 5–17 05–29 4–17 9– 27
Lp(a) (%) 61–74 55–68 28–74 19–70 51–71
Triglycerides (%) 38–56 20–53 29–40 26–60 34–49
Fibrinogen (%) 42–51 51–58 13–16 17–40 15–21
















plasma  processing.  For  primary  plasma  separation,  seve-










Polyclonal  antibodies  against  human APO  B100,  derived 
from sheep, are fixed on Sepharose CL-4B, which bind all 



















Efficient  elimination  of  phytanic  acid,  which  is  eleva-
ted  in  the  rare Refsum’s syndrome,  has been described by 
several  systems,  such as DALI, HELP, and cascade filtra-
tion.  Elimination  is  easily  possible  because  phytanic  acid 
in plasma is largely bound to LDL and VLDL particles [3].
The  chylomicronemia syndrome  is  characterized  by  a 
massive increase of triglyceride-rich plasma lipids. Trigly-
ceride levels exceeding 5,000–10,000 mg/dL can be obser-






















































changes  in medication  immediately  before  the  next  treat-






after  the  end  of  treatment,  and  may  be  accompanied  by 
nausea, vertigo, fatigue, mild headache and vomiting. This 
mild cardiocirculatory instability is mostly induced by the 















plasma  apheresis  systems  to  enhance  protection  from 





























tion  of  low-density  lipoprotein  and  lipoprotein(a)  from  whole 
blood:  results  of  the  first  clinical  long-term  multicenter  study 
using DALI apheresis. J Clin Apheresis 17:161–169





membrane differential filtration  to  lipid filtration:  technological 
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